Sellas Life Sciences Shares Surge 156% After Positive Leukemia Vaccine Trial Results
Shares of Sellas Life Sciences surged 156% in one day after its experimental leukemia vaccine, galinpepimut-S (GPS), showed a 41% reduction in death risk and extended median survival to 24 months in a late-stage trial involving 126 acute myeloid leukemia patients. The company plans to discuss accelerated FDA approval, targeting a 2027 filing. The stock's sharp rise added over $2.38 billion to its market value, reflecting investor optimism about the treatment's potential.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (85/100). Lens Score 44/100.
Outlets measured: economictimes, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (85–85/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 18 Nov, 06:41 am. Other outlets followed.
